BofA reinstates pharma coverage
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to BofA reinstates pharma coverage
December 11, 2024 6:31 AM EST
Deutsche Bank analyst James Shin reiterated a Hold rating and $73.00 price target on Gilead Sciences (NASDAQ: GILD).
The analyst comments "Big picture - GILD's HIV day demonstrated its HIV franchise has potential to extend into FY2035. GILD is trading at ~12x the Street's 2025E EPS ($7.47/sh), >2- turns... More
December 11, 2024 6:24 AM EST
Leerink Partners analyst David Risinger lowered the price target on Pfizer (NYSE: PFE) to $28.00 (from $31.00) while maintaining a Market Perform rating.
The analyst comments "We are lowering our 25E EPS by 10% from $3.12 to $2.82 ahead of the company's 2025 guidance call on Dec 17 at 8:30 am ET; webcast... More
December 11, 2024 6:21 AM EST
Leerink Partners analyst Andrew Berens raised the price target on Gilead Sciences (NASDAQ: GILD) to $99.00 (from $96.00) while maintaining a Outperform rating.
The analyst comments "Leaving Gileads HIV investors event, we reaffirm our optimism that Gilead can appreciably mitigate the impact of Biktarvys... More
